EMA Outlines 60-Day Process for Postmarket Safety Inquiries

Drug Industry Daily
If an EU nation finds a safety issue with a drug and flags it for review, that decision will start a 60-day clock during which a drugmaker will have the opportunity to resolve all concerns about the product or face revocation or modifications to its market authorization.

To View This Article:


Subscribe To Drug Industry Daily